亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

银耳霉素 杜瓦卢马布 肝细胞癌 危险系数 索拉非尼 医学 置信区间 肿瘤科 养生 内科学 泌尿科 外科 癌症 免疫疗法 无容量 易普利姆玛
作者
Ghassan K. Abou‐Alfa,George K.K. Lau,Masatoshi Kudo,Stephen Lam Chan,Robin Kate Kelley,Junji Furuse,Wattana Sukeepaisarnjaroen,Yoon‐Koo Kang,Tu Van Dao,Enrico Narciso De Toni,Lorenza Rimassa,Valeriy Vladimirovich Breder,Alexander Vasilyev,Alexandra Heurgué,Vincent Channing Tam,Kabir Mody,Satheesh Chiradoni Thungappa,Y. Ostapenko,Thomas C. C. Yau,Sérgio Jobim Azevedo
出处
期刊:NEJM evidence [Massachusetts Medical Society]
卷期号:1 (8): EVIDoa2100070-EVIDoa2100070 被引量:1815
标识
DOI:10.1056/evidoa2100070
摘要

BACKGROUND: A single, high priming dose of tremelimumab (anti-cytotoxic T lymphocyte–associated antigen 4) plus durvalumab (anti–programmed cell death ligand-1), an infusion regimen termed STRIDE (Single Tremelimumab Regular Interval Durvalumab), showed encouraging clinical activity and safety in a phase 2 trial of unresectable hepatocellular carcinoma. METHODS: In this global, open-label, phase 3 trial, the majority of the patients we enrolled with unresectable hepatocellular carcinoma and no previous systemic treatment were randomly assigned to receive one of three regimens: tremelimumab (300 mg, one dose) plus durvalumab (1500 mg every 4 weeks; STRIDE), durvalumab (1500 mg every 4 weeks), or sorafenib (400 mg twice daily). The primary objective was overall survival for STRIDE versus sorafenib. Noninferiority for overall survival for durvalumab versus sorafenib was a secondary objective. RESULTS: In total, 1171 patients were randomly assigned to STRIDE (n=393), durvalumab (n=389), or sorafenib (n=389). The median overall survival was 16.43 months (95% confidence interval [CI], 14.16 to 19.58) with STRIDE, 16.56 months (95% CI, 14.06 to 19.12) with durvalumab, and 13.77 months (95% CI, 12.25 to 16.13) with sorafenib. Overall survival at 36 months was 30.7%, 24.7%, and 20.2%, respectively. The overall survival hazard ratio for STRIDE versus sorafenib was 0.78 (96.02% CI, 0.65 to 0.93; P=0.0035). Overall survival with durvalumab monotherapy was noninferior to sorafenib (hazard ratio, 0.86; 95.67% CI, 0.73 to 1.03; noninferiority margin, 1.08). Median progression-free survival was not significantly different among all three groups. Grade 3/4 treatment-emergent adverse events occurred for 50.5% of patients with STRIDE, 37.1% with durvalumab, and 52.4% with sorafenib. CONCLUSIONS: STRIDE significantly improved overall survival versus sorafenib. Durvalumab monotherapy was noninferior to sorafenib for patients with unresectable hepatocellular carcinoma. (Funded by AstraZeneca; ClinicalTrials.gov number, NCT03298451.)
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
3秒前
Maestro_S的应助被纯情的阁采纳,获得30
3秒前
华无剑的应助被纯情的阁采纳,获得10
3秒前
null的应助被纯情的阁采纳,获得10
3秒前
jxjsyf完成签到 ,获得积分10
7秒前
WW发布了新的文献求助10
9秒前
漂亮的半兰完成签到,获得积分10
13秒前
CipherSage的应助被科研通管家采纳,获得10
13秒前
13秒前
null的应助被科研通管家采纳,获得10
14秒前
深情安青的应助被科研通管家采纳,获得10
14秒前
Maestro_S的应助被科研通管家采纳,获得10
14秒前
香蕉觅云的应助被科研通管家采纳,获得10
14秒前
null的应助被科研通管家采纳,获得10
14秒前
Owen的应助被科研通管家采纳,获得10
14秒前
华无剑的应助被科研通管家采纳,获得10
14秒前
null的应助被科研通管家采纳,获得10
14秒前
SciGPT的应助被科研通管家采纳,获得10
15秒前
15秒前
orixero的应助被WW采纳,获得10
18秒前
如果完成签到 ,获得积分10
19秒前
23秒前
h11的应助被noodle采纳,获得10
24秒前
26秒前
甜蜜的紫菜完成签到,获得积分10
31秒前
学术雷锋发布了新的文献求助30
50秒前
yyy完成签到,获得积分10
51秒前
愉快的书桃完成签到,获得积分10
54秒前
1分钟前
隐形曼青的应助被车访枫采纳,获得10
1分钟前
Younger发布了新的文献求助10
1分钟前
sikhwan_完成签到,获得积分10
1分钟前
风趣的夏波完成签到,获得积分10
1分钟前
岛12完成签到,获得积分20
1分钟前
noodle发布了新的文献求助10
1分钟前
sikhwan_发布了新的文献求助10
1分钟前
1分钟前
1分钟前
1分钟前
华无剑的应助被纯情的阁采纳,获得10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158669
求助须知:如何正确求助?哪些是违规求助? 9554462
关于积分的说明 21719186
捐赠科研通 7748228
什么是DOI,文献DOI怎么找? 3427070
关于科研通互助平台的介绍 2551942
邀请新用户注册赠送积分活动 2471308